Holen Sie sich die Stockscreener-App
0.9177
4.32%
-0.0323
Schlusskurs vom Vortag:
$0.95
Offen:
$0.96
24-Stunden-Volumen:
99,148
Relative Volume:
0.28
Marktkapitalisierung:
$11.33M
Einnahmen:
$285.80K
Nettoeinkommen (Verlust:
$-12.60M
KGV:
-0.4648
EPS:
-1.9743
Netto-Cashflow:
$-13.44M
1W Leistung:
+13.62%
1M Leistung:
-2.25%
6M Leistung:
-27.28%
1J Leistung:
-45.57%
1-Tages-Spanne:
$0.90
$0.97
1-Wochen-Bereich:
$0.787
$0.97
52-Wochen-Spanne:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.9152 | 11.76M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.57 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.28 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know - MSN
Aprea Expands Cancer Trial After $30 Million Financing - MyChesCo
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know - sharewise.com
This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Therapeuticsfiles for resale of up to 5.5 million shares by selling stockholdersSEC filing - marketscreener.com
[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7) - Stock Titan
Aprea Therapeutics 1Q Research and Development Expenses $1.6M >APRE - Moomoo
APRE Stock Price, Quote & Chart | APREA THERAPEUTICS INC (NASDAQ:APRE) - ChartMill
Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target - TipRanks
Press Release: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Moomoo
Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating - Moomoo
Aprea Therapeutics, Inc. Q1 2026 10-Q Report – Financials, Risk Factors, and Forward-Looking Statements - Minichart
Aprea Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress - TipRanks
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher - ChartMill
Aprea Therapeutics (NASDAQ: APRE) trims Q1 loss and raises over $34M to extend cash runway - Stock Titan
APREA THERAPEUTICS ($APRE) Releases Q1 2026 Earnings - Quiver Quantitative
Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary - TradingView
Aprea Therapeutics Reports Q1 2026 Results: $30M Financing Boosts APR-1051 Clinical Progress and Extends Cash Runway to 2028 - Minichart
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 Trial - Quiver Quantitative
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall - TradingView
8-K: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo
Aprea (NASDAQ: APRE) extends cash runway and reports Q1 2026 results - Stock Titan
Early tumor responses and $30M cash boost for Aprea cancer drug - Stock Titan
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech - Barchart.com
TradingKey - TradingKey
APRE (Aprea) beats Q4 earnings by 20%, but shares fall 2.3% amid growth concerns.Social Momentum Signals - Newser
APRE (Aprea) Q4 earnings beat expectations with smaller loss than estimated, shares climb 5.66%.Put/Call Ratio - Newser
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target - marketscreener.com
Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential - Investing.com Nigeria
Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential By Investing.com - Investing.com South Africa
APRE | Aprea Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Reverse split and director votes in Aprea Therapeutics (NASDAQ: APRE) 2026 proxy - Stock Titan
[EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan
74.35M shares registered for resale by Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
CatalYm picks ex-Aprea CEO Christian Schade to chair board - Stock Titan
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study - MyChesCo
Aprea Therapeutics (NASDAQ: APRE) reporting group discloses 9.9% stake - Stock Titan
Two life sciences companies with Doylestown connections raise $119M - MSN
APRE Forecast, Price Target & Analyst Ratings | APREA THERAPEUTICS INC (NASDAQ:APRE) - ChartMill
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):